Virus-like particles: Promising platforms with characteristics of DIVA for veterinary vaccine design

Liu, Fuxiao; Wu, Xiaodong; Lin, Li; Ge, Shengxiang; Liu, Zengshan; Wang, Zhiliang

doi:10.1016/j.cimid.2013.02.002

Cited by 26 publications

(20 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, VLPs are able to undergo efficient antigen processing and presentation through either major histocompatibility complex class I or class II molecules, thereby inducing strong humoral and cellular immune responses (Bachmann et al, 1996;Pejawar-Gaddy et al, 2010;Win et al, 2011;Liu et al, 2013). Moreover, VLPs can directly induce dendritic cell maturation, and thus positively regulate costimulatory molecule expression and cytokine secretion, further activating CD8 + T lymphocytes (Bosio et al, 2004;Yang et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Development and characterization of Rift Valley fever virus-like particles

Wang

Zheng

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Rift Valley fever (RVF) is an acute, febrile zoonotic disease that is caused by the RVF virus (RVFV) and spread by arthropod vectors. RVF is currently prevalent in Africa and the Arabian Peninsula, and causes substantial economic losses. Furthermore, this disease poses a serious threat to animal and human health in regions worldwide, making it a serious public health concern. However, RVFV vaccines for human use are still unavailable, and hence there is an urgent need for novel efficient vaccines against RVFV. Vaccine preparation techniques have become a crucial factor in developing new vaccines. In the current study, the N and G protein genes of RVFV were inserted into the pFastBacDual baculovirus expression vector downstream of the pP10 and pPH promoters. The resultant recombinant vector, pFastBacDual-S-M, was transfected into Sf9 insect cells by lipofection. The recombinant baculovirus, named rBac-N-G, was retrieved and infected into Sf9 insect cells to generate RVFV viruslike particles (VLPs). Using polyclonal antibodies against RVFV proteins in immunofluorescence and western blot analyses, we positively identified the presence of the RVFV proteins in VLP preparations. Sucrose density gradient centrifugation and transmission electron microscopy revealed that the morphology of the RVFV VLPs was consistent with previous reports of RVFV virions. This study describes a technique for efficient production of RVFV VLPs, and has laid the foundation for future VLP-based RVFV vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and characterization of Rift Valley fever virus-like particles

Wang

Zheng

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Virus-like particles (VLPs) recently emerged as alternatives to subunit vaccines; these have the advantage that they mimic the organization and conformation of the native virus capsid and envelope, but lack the viral genome [14,15].Given their intrinsic immunogenic properties and high safety profile, VLPs have been generated in different heterologous expression systems and have been tested as vaccine candidates for a variety of viral diseases [16]. In the human vaccines market, six VLP-based vaccines, including three for hepatitis B (Recombivax HB, Engerix B, and GenHevac B), two for human papillomavirus (Gardasil and Cervarix), and one for influenza A (InflexalV), have been developed [16,17].In the veterinary field, a VLP-based vaccine against porcine circovirus type 2 (PCV2), viz., Porcilis PCV, Intervet, has recently been licensed [18].…”

Section: Introductionmentioning

confidence: 99%

Self-Assembly and Release of Peste des Petits Ruminants Virus-Like Particles in an Insect Cell-Baculovirus System and Their Immunogenicity in Mice and Goats

Jin

Sui

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Peste des petits ruminants (PPR) is an acute, febrile, viral disease of small ruminants that has a significant economic impact. For many viral diseases, vaccination with virus-like particles (VLPs) has shown considerable promise as a prophylactic approach; however, the processes of assembly and release of peste des petits ruminants virus (PPRV) VLPs are not well characterized, and their immunogenicity in the host is unknown. In this study, VLPs of PPRV were generated in a baculovirus system through simultaneous expression of PPRV matrix (M) protein and hemaglutin in (H) or fusion (F) protein. The released VLPs showed morphology similar to that of the native virus particles. Subcutaneous injection of these VLPs (PPRV-H, PPRV-F) into mice and goats elicited PPRV-specific IgG production, increased the levels of virus neutralizing antibodies, and promoted lymphocyte proliferation. Without adjuvants, the immune response induced by the PPRV-H VLPs was comparable to that obtained using equivalent amounts of PPRV vaccine. Thus, our results demonstrated that VLPs containing PPRV M protein and H or F protein are potential “differentiating infected from vaccinated animals” (DIVA) vaccine candidates for the surveillance and eradication of PPR.

show abstract

“…In the veterinary field, a vaccine for porcine circovirus type 2 (PCV-2) developed using VLPs has been approved for marketing (Intervet International Ltd., the Netherlands) (17). VLPs can effectively activate APCs and B lymphocytes by virtue of their size, potential and other properties (18,19). Moreover, VLPs can be processed and presented through two pathways, the MHC-II and MHC-I molecular pathways, to induce strong humoral and cellular immune responses (20)(21)(22), which allows DCs to efficiently FIGURE 3 | Enzyme-linked immune spot assay for IL-4 (A) and IFN-γ (B) production by spleen lymphocytes from mice at day 14 after the second immunization.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity Assessment of Rift Valley Fever Virus Virus-Like Particles in BALB/c Mice

Han

Zhao

et al. 2020

Front. Vet. Sci.

View full text Add to dashboard Cite

Rift Valley fever (RVF) is an acute, febrile zoonotic disease that is caused by the RVF virus (RVFV) and is spread by arthropod vectors. Virus-like particle (VLP) vaccines, which have the advantages of strong immunogenicity and safety, play an important role in the prevention of this disease. VLPs for RVFV were successfully prepared by our research group using a baculovirus-insect cell expression system. To study the immunogenicity of these RVFV VLPs, a correct 3rd or 4th generation recombinant baculovirus, rBac-N-G, was identified and used to infect Sf9 cells, which were cultured in suspension at a large scale. Subsequently, cell debris was removed by centrifugation, and the VLPs were concentrated by ultracentrifugation and purified using a sucrose gradient, after which they were used to immunize BALB/c mice by intramuscular injection. The results showed that the RVFV VLPs prepared by our research group could effectively induce mice to produce RVFV neutralizing antibodies and that the prepared VLPs could stimulate mouse spleen cells to produce high levels of the cytokines IL-4 and IFN-γ. Moreover, the proportion of lymphocytes producing IL-4 and IFN-γ in the spleen of mice immunized with RVFV VLPs was significantly increased. Therefore, the RVFV VLPs prepared in this study had strong immunogenicity and could effectively activate humoral and cellular immunity in mice. This study lays a solid foundation for the development of RVFV VLP vaccine candidates and promotes the healthy development of animal husbandry and human public health.

show abstract

Virus-like particles: Promising platforms with characteristics of DIVA for veterinary vaccine design

Cited by 26 publications

References 96 publications

Development and characterization of Rift Valley fever virus-like particles

Development and characterization of Rift Valley fever virus-like particles

Self-Assembly and Release of Peste des Petits Ruminants Virus-Like Particles in an Insect Cell-Baculovirus System and Their Immunogenicity in Mice and Goats

Immunogenicity Assessment of Rift Valley Fever Virus Virus-Like Particles in BALB/c Mice

Contact Info

Product

Resources

About